Clinical trials
Active, not recruiting Prostatic Neoplasms trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
86 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 8 |
| 2015 | 7 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 11 |
| 2021 | 11 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 86 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sunnybrook Health Sciences Centre | 7 |
| CHU de Quebec-Universite Laval | 6 |
| Aragon Pharmaceuticals, Inc. | 5 |
| British Columbia Cancer Agency | 5 |
| Novartis Pharmaceuticals | 5 |
| AstraZeneca | 4 |
| Canadian Cancer Trials Group | 4 |
| NRG Oncology | 4 |
| Sir Mortimer B. Davis - Jewish General Hospital | 4 |
| University Health Network, Toronto | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 86 |
| Neoplasm Metastasis | 4 |
| Disease | 3 |
| Endometrial Neoplasms | 2 |
| Inflammation | 2 |
| Urogenital Neoplasms | 2 |
| Biliary Tract Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Bulbo-Spinal Atrophy, X-Linked | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Trials
Showing 1 to 25 of 86. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.